| 16614-0 |
Cholesterol crystals |
PrThr |
Body fld |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Cholesterol crystals [Presence] in Body fluid by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
16614-0 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Cholest Cry Fld Ql Micro |
|
|
|
|
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chol; Choles; Cholest; Cholest Cry; Cholesterol total; Cholesterols; Crys; Cryst; Crystal; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Lipid; LM; Micro; Micros; Microscopic; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16615-7 |
Cholesterol.total/Cholesterol.in LDL |
MRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol.total/Cholesterol in LDL [Mass Ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16615-7 |
|
|
|
|
Observation |
|
|
|
0 |
Cholest/LDLc SerPl |
|
|
|
Y |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; LDLc; LDL-C; Lipid; Low density lipoprotein cholesterol; Low density lipoprotein cholesterols; Mass concentration ratio; Mass ratio; MCRto; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TC; Tot; Totl |
2.42 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16616-5 |
Cholesterol.in HDL/Cholesterol.in LDL |
MRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in HDL/Cholesterol in LDL [Mass Ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16616-5 |
|
|
|
|
Observation |
|
|
|
0 |
HDLc/LDLc SerPl |
|
|
|
Y |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; HDLc; HDL-C; Heart Disease; High density lipoprotein cholesterols; LDLc; LDL-C; Lipid; Low density lipoprotein cholesterol; Low density lipoprotein cholesterols; Mass concentration ratio; Mass ratio; MCRto; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TCHHDL |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16617-3 |
Choriogonadotropin.intact |
SCnc |
Semen |
Pt |
Qn |
|
|
ACTIVE |
Choriogonadotropin.intact [Moles/volume] in Semen |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16617-3 |
|
|
|
|
Both |
|
|
|
0 |
HCG Intact Smn-sCnc |
|
|
|
Y |
|
CG; Chemistry; Choriogonadotropins total; Chorionic gonadotropin; Chorionic gonadotropin.intact; Ejaculate; Genitourinary; GU; HCG; HCG Intact; Human chorionic gonadotropin; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Sem; Seminal fluid; Smn; SMPLS; Substance concentration; URO; Urology |
2.7 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 16618-1 |
Cladosporium herbarum Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Cladosporium herbarum Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
16618-1 |
|
|
|
|
Both |
|
|
|
0 |
C herbarum Ab Qn |
|
|
|
Y |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; C herbarum; Hormodendrum; m002; m2; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16619-9 |
Clarithromycin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Clarithromycin [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16619-9 |
|
|
|
|
Both |
|
|
|
0 |
Clarithro SerPl-mCnc |
|
|
|
Y |
|
Biaxin; Claripen; DRUG/TOXICOLOGY; Drugs; Klacid; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 1662-6 |
11-Ketoetiocholanolone |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
11-Ketoetiocholanolone [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHEM |
|
1662-6 |
|
|
|
|
Both |
|
|
|
0 |
11Ketoetioch Ser-mCnc |
|
|
|
Y |
|
11Ketoetioch; Chemistry; Ketoetiochol; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 16620-7 |
Clarithromycin+Ethambutol |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Clarithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
16620-7 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Clarithro+Ethamb Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Biaxin; Claripen; Clarithro+Ethamb; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; Klacid; Minimum inhibitory concentration; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16621-5 |
Clindamycin^peak |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Clindamycin [Mass/volume] in Serum or Plasma --peak |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16621-5 |
|
|
|
|
Both |
|
|
|
0 |
Clindamycin Peak SerPl-mCnc |
|
|
|
Y |
|
c306; Cleocin; CLIJ; Dalacin; DRUG/TOXICOLOGY; Drugs; ID; Infectious Disease; InfectiousDisease; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Post; Postdose; Post-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sobelin; SR; Topical |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16622-3 |
Clindamycin^trough |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Clindamycin [Mass/volume] in Serum or Plasma --trough |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16622-3 |
|
|
|
|
Both |
|
|
|
0 |
Clindamycin Trough SerPl-mCnc |
|
|
|
Y |
|
c306; Cleocin; CLIJ; Dalacin; DRUG/TOXICOLOGY; Drugs; ID; Infectious Disease; InfectiousDisease; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sobelin; SR; Topical |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16623-1 |
Clofazimine |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Clofazimine [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
16623-1 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Clofazamine Islt MIC |
|
|
|
Y |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Clofazamine; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16624-9 |
clomiPRAMINE |
ACnc |
Milk |
Pt |
Qn |
|
|
DISCOURAGED |
clomiPRAMINE [Units/volume] in Milk |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16624-9 |
|
|
|
|
Both |
|
|
|
0 |
clomiPRAMINE Mlk-aCnc |
|
|
|
Y |
|
Anafranil; Anofranil; Arbitrary concentration; Clom; Clomip; DRUG/TOXICOLOGY; Drugs; MLK; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16625-6 |
clomiPRAMINE |
MCnc |
Milk |
Pt |
Qn |
|
|
ACTIVE |
clomiPRAMINE [Mass/volume] in Milk |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16625-6 |
|
|
|
|
Both |
|
|
|
0 |
clomiPRAMINE Mlk-mCnc |
|
|
|
Y |
|
Anafranil; Anofranil; Clom; Clomip; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Mlk; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.42 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16626-4 |
Clostridium tetani Ab^1st specimen |
ACnc |
Ser |
Pt |
Qn |
|
|
DISCOURAGED |
Clostridium tetani Ab [Units/volume] in Serum --1st specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16626-4 |
|
|
|
|
Both |
|
|
|
0 |
C tetani Ab sp1 Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Acute specimen; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; C tetani; First; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Pre immunization; QNT; Quan; Quant; Quantitative; Random; Serum; sp1; Spec; SR; Tet; Tetanus |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16627-2 |
Clostridium tetani Ab^2nd specimen |
ACnc |
Ser |
Pt |
Qn |
|
|
DISCOURAGED |
Clostridium tetani Ab [Units/volume] in Serum --2nd specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16627-2 |
|
|
|
|
Both |
|
|
|
0 |
C tetani Ab sp2 Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; C tetani; Convalescent; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Post immunization; QNT; Quan; Quant; Quantitative; Random; Second; Serum; sp2; Spec; SR; Tet; Tetanus |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16628-0 |
Cloxacillin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cloxacillin [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16628-0 |
|
|
|
|
Both |
|
|
|
0 |
Cloxacillin SerPl-mCnc |
|
|
|
Y |
|
Alclox; Ampiclox; Amplium; APO-CLOXI; Austrastaph; Clocillin; Cloxin; DRUG/TOXICOLOGY; Drugs; Ekvacillin; Level; Mass concentration; Novo-cloxi; Nu-cloxi; Orbenin; Penstapho n; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tegopen |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16629-8 |
Coagulation surface induced |
Time |
Bld^Control |
Pt |
Qn |
Coag |
|
DEPRECATED |
Deprecated Activated partial thrombplastin time (aPTT) in Blood from control by Coagulation assay |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
16629-8 |
|
Coag |
|
|
|
|
|
|
0 |
Deprecated aPTT Bld Cont Qn |
|
|
|
|
|
Activated partial thromboplastin time; aPTT; Blood; Clot; Clottable; Coag; Coagulation assay; Contrl; Hematology; Heme; Little(A)PTT; Normal; Partial Thromboplastin Time; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube; WB; Whole blood |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 1663-4 |
11-Oxycorticosterone |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
11-Oxycorticosterone [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHEM |
|
1663-4 |
|
|
|
|
Both |
|
|
|
0 |
11oxyCorticosterone Ser-mCnc |
|
|
|
Y |
|
11oxyCorticosterone; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
1 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 16630-6 |
Coagulation surface induced |
Time |
Bld^Control |
Pt |
Qn |
Coag.saline 1:1 |
|
ACTIVE |
aPTT in Control Blood by Coagulation 1:1 saline |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
16630-6 |
|
Coag.saline 1:1 |
|
|
Observation |
|
|
|
0 |
aPTT Cont Bld 1:1 saline |
|
|
|
Y |
|
1:1 saline; Activated partial thromboplastin time; aPTT; Blood; Clot; Clottable; Coag; Coagulation assay; Contrl; Hematology; Heme; i; Little(A)PTT; Normal; Partial Thromboplastin Time; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube; WB; Whole blood |
2.73 |
1.0l |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 16631-4 |
Coagulation surface induced |
Time |
Bld |
Pt |
Qn |
Coag.saline 1:1 |
|
ACTIVE |
aPTT in Blood by Coagulation 1:1 saline |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
16631-4 |
|
Coag.saline 1:1 |
|
|
Both |
|
|
|
0 |
aPTT Bld 1:1 saline |
|
|
|
Y |
|
1:1 saline; Activated partial thromboplastin time; aPTT; Blood; Clot; Clottable; Coag; Coagulation assay; Hematology; Heme; i; Little(A)PTT; Partial Thromboplastin Time; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube; WB; Whole blood |
2.73 |
1.0l |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 16632-2 |
Cocaethylene |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Cocaethylene [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16632-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Cocaethylene Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Cocaine/Ethanol By-Product; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16633-0 |
Cocaine |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Cocaine [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16633-0 |
|
|
|
|
Both |
|
|
|
0 |
Cocaine Bld Ql |
|
|
|
|
|
Addiction; Benzoylmethylecgonine; Blood; Coke; Crack; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Ecgonine methyl ester benzoate; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; Snow; WB; Whole blood |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16634-8 |
Coccidioides immitis Ab |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Coccidioides immitis Ab [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16634-8 |
|
|
|
|
Both |
|
|
|
0 |
C immitis Ab CSF-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B immitis; Blastomycoides immitis; C esteriformis; C immitis; Cerebral spinal fluid; Cerebrospinal Fl; Coccidioides esteriformis; Coccidiomycosis; Coccio; G immite; G louisianoideum; G metaeuropea; Geotrichum immite; Glenospora metaeuropea; Glenosporum louisianoideum; ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; P esteriformis; P mazzai; Point in time; Posadasia esteriformis; Pseudococcidioides mazzai; QNT; Quan; Quant; Quantitative; Random; San Joaquin Valley fever; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; T proteolyticum; Trichosporon proteolyticum; Valley fever |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16635-5 |
Coccidioides immitis Ab.IgA |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Coccidioides immitis IgA Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16635-5 |
|
IA |
|
|
Both |
|
|
|
0 |
C immitis IgA Ser IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B immitis; Blastomycoides immitis; C esteriformis; C immitis; Coccidioides esteriformis; Coccidiomycosis; Coccio; EIA; ELFA; ELISA; Enzyme immunoassay; G immite; G louisianoideum; G metaeuropea; Geotrichum immite; Glenospora metaeuropea; Glenosporum louisianoideum; IAA; ID; Immune globulin A; Immunoglobulin A; Infectious Disease; InfectiousDisease; MEIA; Microbiology; P esteriformis; P mazzai; Point in time; Posadasia esteriformis; Pseudococcidioides mazzai; QNT; Quan; Quant; Quantitative; Random; San Joaquin Valley fever; Serum; SR; SUDS; T proteolyticum; Trichosporon proteolyticum; Valley fever |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16636-3 |
Coccidioides immitis Ab.IgA |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Coccidioides immitis IgA Ab [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16636-3 |
|
|
|
|
Both |
|
|
|
0 |
C immitis IgA CSF-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B immitis; Blastomycoides immitis; C esteriformis; C immitis; Cerebral spinal fluid; Cerebrospinal Fl; Coccidioides esteriformis; Coccidiomycosis; Coccio; G immite; G louisianoideum; G metaeuropea; Geotrichum immite; Glenospora metaeuropea; Glenosporum louisianoideum; ID; Immune globulin A; Immunoglobulin A; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; P esteriformis; P mazzai; Point in time; Posadasia esteriformis; Pseudococcidioides mazzai; QNT; Quan; Quant; Quantitative; Random; San Joaquin Valley fever; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; T proteolyticum; Trichosporon proteolyticum; Valley fever |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
